title: Analysis of Epstein-Barr virus-regulated host gene expression changes through primary B-cell outgrowth reveals delayed kinetics of latent membrane protein 1-mediated NF-κB activation.
abstract: Epstein-Barr virus (EBV) is an oncogenic human herpesvirus that dramatically reorganizes host gene expression to immortalize primary B cells. In this study, we analyzed EBV-regulated host gene expression changes following primary B-cell infection, both during initial proliferation and through transformation into lymphoblastoid cell lines (LCLs). While most EBV-regulated mRNAs were changed during the transition from resting, uninfected B cells through initial B-cell proliferation, a substantial number of mRNAs changed uniquely from early proliferation through LCL outgrowth. We identified constitutively and dynamically EBV-regulated biological processes, protein classes, and targets of specific transcription factors. Early after infection, genes associated with proliferation, stress responses, and the p53 pathway were highly enriched. However, the transition from early to long-term outgrowth was characterized by genes involved in the inhibition of apoptosis, the actin cytoskeleton, and NF-κB activity. It was previously thought that the major viral protein responsible for NF-κB activation, latent membrane protein 1 (LMP1), is expressed within 2 days after infection. Our data indicate that while this is true, LCL-level LMP1 expression and NF-κB activity are not evident until 3 weeks after primary B-cell infection. Furthermore, heterologous NF-κB activation during the first week after infection increased the transformation efficiency, while early NF-κB inhibition had no effect on transformation. Rather, inhibition of NF-κB was not toxic to EBV-infected cells until LMP1 levels and NF-κB activity were high. These data collectively highlight the dynamic nature of EBV-regulated host gene expression and support the notion that early EBV-infected proliferating B cells have a fundamentally distinct growth and survival phenotype from that of LCLs.
authors.affiliation: Department of Molecular Genetics and Microbiology, Center for Virology, Duke University Medical Center, Durham, North Carolina, USA.
authors.forename: Alexander M
authors.initials: AM
authors.lastname: Price
authors.forename: Jason P
authors.initials: JP
authors.lastname: Tourigny
authors.forename: Eleonora
authors.initials: E
authors.lastname: Forte
authors.forename: Raul E
authors.initials: RE
authors.lastname: Salinas
authors.forename: Sandeep S
authors.initials: SS
authors.lastname: Dave
authors.forename: Micah A
authors.initials: MA
authors.lastname: Luftig
mesh_terms: D008841:Actin Cytoskeleton / Q000235:genetics; D017209:Apoptosis / Q000235:genetics; D001402:B-Lymphocytes / Q000166:cytology* / Q000821:virology*; D049109:Cell Proliferation; D002472:Cell Transformation, Viral / Q000235:genetics*; D002478:Cells, Cultured; D005786:Gene Expression Regulation; D004854:Herpesvirus 4, Human / Q000235:genetics / Q000254:growth & development / Q000378:metabolism*; D006801:Humans; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D012367:RNA, Viral / Q000235:genetics; D016159:Tumor Suppressor Protein p53 / Q000235:genetics; D014763:Viral Matrix Proteins / Q000096:biosynthesis / Q000378:metabolism*; D014779:Virus Replication / Q000235:genetics
chemical_list: C037662:EBV-associated membrane antigen, Epstein-Barr virus; D016328:NF-kappa B; D012333:RNA, Messenger; D012367:RNA, Viral; D016159:Tumor Suppressor Protein p53; D014763:Viral Matrix Proteins